brainscienceblogs.com

New Medicine Brought to Life by the World's Top Researchers

we know psychiatry.

JUST IN:
Chantix & Zyban Receive Boxed Warnings for Serious Psychiatric Symptoms

RECENT SUBMISSIONS:

Switching To Duloxetine Remits Ziprasidone – Associated Urinary Incontinence And Improves Neuropsychiatric Behavior In Dementia: Possible Relationship Of Incontinence To 5HT2 Receptor Blockade
Edward C. Lauterbach, MD and Florence Baralatei, MD

EFFICACY OF OMEGA 3 FATTY ACIDS IN MOOD DISORDERS – A SYSTEMATIC REVIEW AND METAANALYSIS
Nina V Kraguljac, MD, Victor M Montori, MD, Mani Pavuluri, MD, PhD, High S Chai, PhD., Brian S Wilson, Sencan S Unal, MD

Statistical Strategies for Randomized Controlled Clinical Trials to Detect Differential Onset of Action
Andrew C. Leon, PhD

Recent-Onset Schizophrenia and Adolescent Cannabis Use: MRI Evidence for Structural Hyperconnectivity?
Bart D. Peters, MD, Lieuwe de Haan, MD, PhD, Erik-Jan Vlieger, MD, PhD, Charles B. Majoie, MD, PhD, Gerard J. den Heeten, MD, PhD, Don H. Linszen MD, PhD

Clinical Significance of Transcranial Magnetic Stimulation (TMS) in the Treatment of Pharmacoresistant Depression: Synthesis of Recent Data
Mark A. Demitrack, MD, Michael E. Thase, MD

Desvenlafaxineand Venlafaxine Exert Minimal In Vitro Inhibition of Human Cytochrome
P450 and P-glycoprotein Activities

Aram Oganesian, PhD, Adam D. Shilling, PhD, Ruth Young-Sciame, BS, Judy Tran, BS, Adiba Watanyar, BS, Farooq Azam, MS, John Kao, Louis Leung, PhD

Revisiting the Effectiveness of Standard Antidepressants in
Bipolar Disorder: Are Monoamine Oxidase Inhibitors Superior?
Alan G. Mallinger, MD, Ellen Frank, PhD, Michael E. Thase, MD
Michelle M. Barwell, MD, Nancy DiazGranados, MD, David A. Luckenbaugh, MA, David J. Kupfer, MD

NEW AND NOTEWORTHY:

Atypical Antipsychotic Drugs and Diabetes Mellitus in the US Food
and Drug Administration Adverse Event Database: A Systematic Bayesian Signal Detection Analysis
By Ross A. Baker, A ndrei Pikalov, Quynh-Van Tran, Tatyana Kremenets, Ramin B. Arani,
P. Murali Doraiswamy
Psychopharmacology Bulletin. 2009;42(1):11–31

Bipolar-I Patient Characteristics Associated with Differences in Antimanic Medication Prescribing
By Alisa B. Busch, Richard G. Frank, Gary Sachs, Sharon-Lise T. Normand
Psychopharmacology Bulletin. 2009;42(1):35–49

Neuropsychological Functioning in Patients with Posttraumatic Stress Disorder Following Short-Term Paroxetine Treatment
By Negar Fani, Noriyuki Kitayama, Ali Ashraf, Lai Reed, Nadeem Afzal, Farhan Jawed,
J. Douglas Bremner
Psychopharmacology Bulletin. 2009;42(1):53–68

Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder:An open-label trial
By Jamie D. Feusner, Lauren Kerwin, Sanjaya Saxena, Alexander Bystritsky
Psychopharmacology Bulletin. 2009;42(1):81–93.

Does risperidone Improve Hyperacusia in Children with Autism?
By Ahmad Ghanizadeh
Psychopharmacology Bulletin. 2009;42(1):108–110

Early Symptom Change Prediction of Remission in Depression Treatment
By Martin M. Katz, Adam L. Meyers, Apurva Prakash, Paula J. Gaynor, John P. Houston
Psychopharmacology Bulletin. 2009;42(1):94–107.

An Open-Label Assessment of Aripiprazole in the Treatment of PTSD
By Sophie Robert, Mark B. Hamner, Valerie L. Durkalski, Mary W. Brown, Helen G. Ulmer
Psychopharmacology Bulletin. 2009;42(1):69–80.

Frequency of Stimulant Treatment and of Stimulant-Associated Mania/Hypomania in Bipolar Disorder Patients
By Aliza P. Wingo, S. Nassir Ghaemi
Psychopharmacology Bulletin. 2008;41(4):37–47.

REVAMP - Research Evaluating the Value of Augmenting Medication with Psychotherapy: Rationale and Design
By Madhukar H. Trivedi, James H. Kocsis, Michael E. Thase, David W. Morris, Stephen R. Wisniewski, Andrew C. Leon, Alan J. Gelenberg, Daniel N. Klein, George Niederehe, Alan F. Schatzberg, Philip T. Ninan, Martin B. Keller
Psychopharmacology Bulletin. 2008;41(4):5–33.

Correlates of Functioning in Bipolar Disorder
By Laszlo Gyulai, Mark S. Bauer, Lauren B. Marangell, Ellen B. Dennehy, Michael E. Thase, Michael W. Otto, Hongwei Zhang, Stephen R. Wisniewski, David J. Miklowitz, Mark H. Rapaport, Claudia F. Baldassano, and Gary S. Sachs for the STEP-BD Investigators
Psychopharmacology Bulletin. 2008;41(4):51–64.

Exercise for Depression: Efficacy, Safety and Clinical Trial Implications
By Boadie W. Dunlop, Rachel L. Self
Psychopharmacology Bulletin. 2008;41(4):65–75.

Treatment Target in Schizophrenia: A Critical Review and a Clinical Suggestion
By Takefumi Suzuki, Hiroyuki Uchida, Koichiro Watanabe, Haruo Kashima
Psychopharmacology Bulletin. 2008;41(4):80–102.

Can Fluoxetine Alone Cause Serotonin Syndrome in Adolescents?
By Ahmad Ghanizadeh, MohammadJavad Ghanizadeh, Masoomah Seifoori
Psychopharmacology Bulletin. 2008;41(4):76–79.

The Efficacy and Tolerability of Once-Daily Extended Release Quetiapine Fumarate in Hospitalized Patients with Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Study
By Jean-Pierre Lindenmayer, David Brown, Sherry Liu, Martin Brecher, and Didier Meulien, on behalf of the Study 41 investigators
Psychopharmacology Bulletin. 2008;41(3):11-35.

Psychometric Evaluation of a Patient-Rated Troubling Symptom Scale for
Generalized Anxiety Disorder Clinical Trials
By Gahan J. Pandina, Dennis A. Revicki, Leah Kleinman, Ibrahim Turkoz, Jasmanda Wu, Ramy Mahmoud, Georges M. Gharabawi
Psychopharmacology Bulletin. 2008;41(3):68–90.

A Major Change of Prescribing Pattern in Absence of Adequate Evidence: Benzodiazepines Versus Newer Antidepressants in Anxiety Disorders
By Patricia Berney, MD, Demian Halperin, MD, Rodrigo Tango, MD, Isabelle Daeniker-Dayer, MD and
Pierre Schulz, MD
Psychopharmacology Bulletin. 2008;41(3):39–47

Developing and Testing Adaptive Treatment Strategies Using Substance-Induced Psychosis as an Example
By Ree Dawson, Alan I. Green, Robert E. Drake, Thomas H. McGlashan, Bella Schanzer, Philip W. Lavori
Psychopharmacology Bulletin. 2008;41(3):51–67.

Are SNRIs More Effective than SSRIs? A Review of the Current State of the Controversy
By Michael E. Thase, MD. Psychopharmacol Bull.2008; 41(2):58-85.

While all readers are welcome to explore brainscience.com, this site is designed for mental healthrofessionals with a keen interest in the brain sciences. Many articles are technical, and originate from peer-review journals. Best of luck and good reading. —The Editors

Michael E. Thase, MD, Editor-In-ChiefA Long-Revered Resource in Academia

Published from 1965 until 1999 by the National Institute of Mental Health (NIMH), Psychopharmacology BULLETIN forged its path just as psychiatry itself was embarking on its golden era of treatment breakthroughs and recognition as a valid and independent field of medicine. Within months of MedWorks Media acquiring the rights to the title, the beloved Psychopharmacology BULLETIN was given a facelift, and a powerhouse Editor

The ABCs of Trends: A Mission of Influence

[ndexed in a variety of databases including Index Medicus and PubMed since 1966, Bulletin’s influential name carries with it a certain responsibility to make sense of the trends in medicine for clinicians. With the primary catalyst for cutting-edge remission treatment in anxiety and depression—Michael E. Thase, MD—on board as the new Editor, the Bulletin will cover evidence-based medicine as a section in every issue, along with original works on drug interactions and neuroscientific updates in translational work and imaging. Dr. Thase’s focus is on the future, on broadening the Bulletin’s scope, fostering an ability to engage readers actively, and expanding its already formidable sphere of influence in the field of neuropsychiatry. editorial board masthead